Clinical trial · Observational
Liquid Biopsy for Detection of Driver Mutation in NSCLC
Liquid Biopsy for Detection of Driver Mutation in Diagnostic and Prognostic of NSCLC
NCT02778854CI-TRIAL-00031988unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate the diagnostic and prognostic efficacy of liquid biopsy in different specimens and in different methods compared with tissue detection .
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| detection of driver mutation | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- cohort 1
- description
- Participants are recruited for diagnostic test
- interventionNames
- Genetic: detection of driver mutation
- label
- cohort 2
- description
- participants are recruited for follow-up
- interventionNames
- Genetic: detection of driver mutation
Primary outcomes (1)
- measure
- concordance between tissue and plasma using detection method such as droplet digital PCR(ddPCR) or next generation sequencing(NGS) to detect the driver mutation in NSCLC
- timeFrame
- 6 months
Secondary outcomes (4)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 85 Years
Show eligibility criteria text
cohort 1 Inclusion Criteria: * patients newly diagnosed with NSCLC confirmed by tissue biopsy and going to receive the detection of gene mutation or patients have obtained drug-resistance after receiving molecular target therapy and plan to re-biopsy. * Age ≥ 18 years * newly diagnosed patients have not received TKI and chemotherapy * patients who are drug-resistant have not received next-generation TKI Exclusion Criteria: * patients who have more than one type of carcinoma * patients who reject to sign the informed consent from cohort 2 Inclusion Criteria: * patients from cohort1 with sensitive driver mutation and plan to receive TKI therapy * patients will have regular follow-up in Chinese people liberation army general hospital every month. Exclusion Criteria: * patients who are refused to provide the informed consent from
References
Publications (1)
- DERIVEDWu Z, Yang Z, Li CS, Zhao W, Liang ZX, Dai Y, Zhu Q, Miao KL, Cui DH, Chen LA. Differences in the genomic profiles of cell-free DNA between plasma, sputum, urine, and tumor tissue in advanced NSCLC. Cancer Med. 2019 Mar;8(3):910-919. doi: 10.1002/cam4.1935. Epub 2019 Feb 14. PMID 30767431